Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors: Cytokinetic effects on bone marrow hematopoietic progenitors

International Journal of Oncology

Volumn 9, Issue 5, 1996, Pages 971-976

  Danova, M ^a   Mazzini, G ^b   Alberici, R ^b   Lucotti, C ^a   Palmeri, S ^c   Fincato, G ^d   Cazzola, M ^a   Riccardi, A ^a   Ascari, E ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Healthcare Risk Management   (Italy)

Author keywords

cell kinetics; dose intensive chemotherapy; flow cytometry; GM CSF; hematopoietic progenitor cells; IL 3; myeloprotection

Indexed keywords

BROXURIDINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CELL KINETICS; CLINICAL ARTICLE; CLINICAL TRIAL; DNA CONTENT; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0029907650     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vose JM and Armitage JO: Clinical applications of hematopoietic growth factors. J Clin Oncol 13: 1023-1035, 1995.
2. Steward WP: Granulocyte and granulocyte-macrophage colony stimulating factors. Lancet 342: 1153-1157, 1993.
3. Aglietta M, Piacibello W, Sanavio F, et al: Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 83: 551-557, 1989.
4. Biesma B, Willemse PHB, Mulder NH, et al: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80: 1141-1148, 1992.
5. Postmus PE, Gietema JA, Damsma O, et al: Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study. J Clin Oncol 10: 1131-1140, 1992.
6. Rinehart J, Margolin KM, Triozzi P, et al: Phase I trial of recombinant interleukin-3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a Southwest Oncology Group Study. Clin Cancer Res 1: 1139-1144, 1995.
7. Veldhuis GJ, Willemse PHB, van Gameren MM, et al: Recombinant human inteleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. J Clin Oncol 13: 733-740, 1995.
8. Leary AG, Yang YC, Clark SC, et al: Recombinant gibbon interleukin-3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 70: 1343-1348, 1987.
9. Donahue RE, Seehra J, Metzger M, et al: Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241: 1820-1823, 1988.
10. Brugger W, Frish J, Schulz G, et al: Sequential administration of Interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide and cisplatin. J Clin Oncol 10: 1452-1459, 1992.
11. O'Shaughnessy JA, Venzon DJ, Gossard M, et al: A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAG (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 85: 2913-2921, 1995.
12. Hornung RL and Longo DL: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80: 77-78, 1992.
13. Moore MAS: Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? Blood 80: 3-7, 1992.
14. Aglietta M, Monzeglio C, Pasquino P, et al: Short-term administration of granulocyte-macrophage colony-stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 72: 2970-2973, 1993.
15. Aglietta M, Sanavio F, Stacchini A, et al: Interleukin-3 in vivo: kinetic of response of target cells. Blood 82: 2054-2061, 1993.
16. Rosti V, Bergamaschi G, Lucotti C, et al: Oligodeoxynucletides antisense to c-abl specifically inhibit entry into S-phase of CD34-positive hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood 86: 3387-3393, 1995.
17. Tafuto S, Abate G, D'Andrea P, et al: A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. Eur J Cancer 31: 46-49, 1995.
18. Broxmeyer HE, Cooper S, Wiliams DE, et al: Effects of purified recombinant human granulocyte-macrophage colony-stimulating factor on growth characteristics of bone marrow hematopoietic progenitors/precursors in patients on a phase I clinical trial. Exp Hematol 16: 594-602, 1988.
19. Lord BI, Bronchud MH, Owens S, et al: The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86: 9499-9503, 1989.
20. Lord BI, Gurney H, Chang J, et al: Haemopoietic cell kinetics in humans treated with rGM-CSF. Int J Cancer 50: 26-31, 1992.
21. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, et al: Abrogating chemotherapy-induced myeclosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 10: 1266-1277, 1992.
22. Riccardi A, Danova M, Paccagnella A, et al: Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with GM-CSF. Ann Hematol 66: 185-193, 1993.
23. Broxmeyer HE, Benninger L, Patel SR, et al: Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 22: 100-102, 1994.
24. Danova M, Rosti V, Mazzini G, et al: Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. Int J Cancer 63: 1-6, 1995.
25. Broxmeyer HE, Benninger L, Cooper S, et al: Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma. Exp Hematol 23: 335-340, 1995.
26. + cell separation. In: Hematopoietic Stem Cells. Wunder E, Sovalat H, Hénon PR and Serke S (eds). Alpha Med Press, Dayton, Ohio, USA, pp 183-200, 1994.
27. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77: 400-409, 1991.
28. Giordano M, Danova M, Mazzini G, et al: Cell kinetics with in vivo bromodeoxyuridine assay, proliferating cell nuclear antigen expression and DNA flow cytometry: prognostic significance in acute non-lymphoblastic leukemia. Cancer 71: 2739-2742, 1993.
29. Danova M, Riccardi A, Ucci G, et al: Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytometric study. Br J Cancer 62: 781-785, 1990.
30. Lemoli RM, Fortuna A, Fogli M, et al: Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Exp Hematol 23: 1520-1526, 1995.
31. Vadhan-Raj S, Papadopoulos NE, Burgess MA, et al: Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 121: 715-719, 1994.
32. Vahan-Raj S, Broxmeyer HE, Andreef M, et al: In vivo biological effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis. Blood 86: 2089-2105, 1995.
33. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomized study in patients with advanced breast cancer. Br J Cancer 69: 385-391, 1994.
34. Ardizzoni A, Pennucci MC, Danova M, et al: Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. Br J Cancer, (In press).
35. Fay JW, Lazarus H, Herzig R, Saez R, et al: Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A phase I/II multicenter study. Blood 84: 2151-2157, 1994.